Valuation : Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 8.79B 1.31B 1.13B 1.06B 968M 1.81B 124B 1.82B 12.52B 4.86B 63.42B 4.92B 4.82B 205B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 7.95B 1.19B 1.02B 959M 876M 1.64B 112B 1.65B 11.33B 4.39B 57.37B 4.45B 4.36B 185B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.63%
Yield 2024 *
-
Yield 2025 -
08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-14 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-15 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
25-10-28 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-04 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
25-05-27 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25-04-25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-17 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
25-03-14 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
25-03-12 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
25-03-10 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day-7.29%
1 week-18.93%
Current month-9.84%
1 month+34.93%
3 months+39.72%
6 months+21.23%
Current year+28.34%
1 week 3.9
Extreme 3.9
4.75
1 month 2.82
Extreme 2.82
5.1
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 2022-12-25
Corporate Officer/Principal 42 2018-04-17
Corporate Officer/Principal 40 2019-05-22
Director TitleAgeSince
Director/Board Member 40 2025-03-13
Director/Board Member 53 2022-11-10
Director/Board Member 42 2022-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/25 Sell 587,500 0.0283%
7/2/25 Sell

Director

259,600 0.0125%
7/2/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-7.29%-18.93%+13.54%+81.57% 1.31B
-0.89%-1.09%+19.16%+67.77% 48.26B
-1.72%-1.15%+45.80%+117.34% 40.5B
-0.70%-2.70%-10.84%+11.79% 11.85B
-2.01%-5.96%+10.47%+76.64% 11.83B
+2.31%0.00%+26.67%+153.33% 9.36B
+0.08%-4.11%+24.83%+43.80% 7.5B
-1.67%-0.35%+41.04%-11.59% 7.37B
-0.89%-3.09%+18.78%+207.82% 7.28B
-0.16%-2.36%-46.14%+16.28% 5.19B
Average -1.29%-2.87%+14.33%+76.48% 15.05B
Weighted average by Cap. -1.01%-1.78%+22.79%+82.77%

Financials

2024 2025
Net sales 2.44B 364M 313M 294M 269M 503M 34.41B 506M 3.48B 1.35B 17.62B 1.37B 1.34B 56.91B 2.14B 319M 274M 258M 235M 440M 30.11B 442M 3.04B 1.18B 15.42B 1.2B 1.17B 49.79B
Net income 233M 34.73M 29.86M 28.08M 25.65M 47.95M 3.28B 48.22M 332M 129M 1.68B 130M 128M 5.43B 377M 56.24M 48.36M 45.47M 41.53M 77.64M 5.31B 78.08M 537M 208M 2.72B 211M 207M 8.79B
Net Debt -509M -75.91M -65.27M -61.37M -56.05M -105M -7.17B -105M -725M -281M -3.67B -285M -279M -11.86B -838M -125M -108M -101M -92.34M -173M -11.81B -174M -1.19B -463M -6.05B -470M -459M -19.54B
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
26-09-04 CN¥3.940 -7.29% 446,943,774
26-09-03 CN¥4.250 -6.18% 623,368,882
26-09-02 CN¥4.530 +4.14% 683,444,456
26-09-01 CN¥4.350 -0.46% 627,052,255
26-08-31 CN¥4.370 -10.08% 666,497,715

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002437 Stock